Novo Nordisk A/S : Victoza(R) label in the US updated to include datashowing superior efficacy when compared to Januvia(R)
Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes
BAGSVAERD, DENMARK, Apr 06, 2012 (Menafn - MARKETWIRE via COMTEX) --Novo Nordisk today announced that the US Food and DrugAdministration (FDA) has approved to update the product label forVictoza(R) (liraglutide [rDNA] injection) to include data showingsuperior blood sugar control and weight reduction when compared toJanuvia(R) (sitagliptin).
Company announcement 22 2012:http://hugin.info/2013/R/1600926/505405.pdf
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrantsthat:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
Tel: (45) 3079 3573
Klaus Bulow Davidsen
Tel: (45) 4442 3176
Frank Daniel Mersebach
Tel: (45) 4442 0604
Lars Borup Jacobsen
Tel: (45) 3075 3479
In North America:
Tel: (1) 609 216-5240
Tel: (1) 609 786 4575
SOURCE: Novo Nordisk A/S
Copyright 2012 Marketwire, Inc., All rights reserved.